---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-032763"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:27:08.433830+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Oncolytics completes continuance to BC; expects Nevada domestication by March 31

## Summary
- First step completed March 17: continuance from Alberta to British Columbia under BCBCA.
- Second step expected March 31: domestication to Nevada; shares continue on Nasdaq as ONCY.
- New CUSIP 68237V103 and ISIN US68237V1035 effective April 1; no name change.
- Shareholder rights modified per BCBCA and will change under Nevada law; approved Jan 15, 2026.
- Outstanding common shares unchanged; no impact on trading symbol or exchange listing.

## SEC filing metadata
- accession: 0001104659-26-032763
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000110465926032763/0001104659-26-032763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000110465926032763/tm269428d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-032763
- JSON: https://secwatch.observer/filing/0001104659-26-032763.json
- Plain text: https://secwatch.observer/filing/0001104659-26-032763.txt

## Source-grounded claims
- claim_id: fa6fd44d4cfd74b8b7e4b9f51b1d35a6f9142ed2
  claim: ONCOLYTICS BIOTECH INC: Adopted continuation application with new Notice of Articles and Articles of Oncolytics British Columbia, changing governing documents from Alberta to British Columbia corporate law.
  evidence_excerpt: In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Oncolytics British Columbia (the “Notice of Articles”) and the Articles of Oncolytics British Columbia (the “Articles”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1129928/000110465926032763/0001104659-26-032763-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.